1.08

1.82% -0.02

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $1.08, with a volume of 535.65K. It is down -1.82% in the last 24 hours and down -3.57% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$1.10

Open:

$1.09

24h Volume:

535.65K

Relative Volume:

0.40

Market Cap:

$273.14M

Revenue:

$14.78M

Net Income/Loss:

$-64.01M

P/E Ratio:

-3.7591

EPS:

-0.2873

Net Cash Flow:

$-22.59M

1W Performance:

-2.70%

1M Performance:

-3.57%

6M Performance:

-44.62%

1Y Performance:

-10.00%

1-Day Range:

$1.08

$1.105

1-Week Range:

$1.08

$1.135

52-Week Range:

$1.00

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2026-08-11

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	1.08	273.14M	14.78M	-64.01M	-22.59M	-0.2873
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Aug 15, 2026

LCTX Q2 2026 Earnings: Wider-Than-Expected Loss Keeps Focus on Cell Therapy PipelineEPS Growth Rate - Vinanet

Aug 15, 2026

Aug 14, 2026

LCTX Q2 2026 Earnings: Slight EPS Miss Overshadowed as Shares Rise $0.94Revenue Surprise History - Vinanet

Aug 14, 2026

LCTX Q2 2026 Earnings: Modest EPS Miss Overshadowed by Clinical-Stage FocusOne-Time Loss Impact - Vinanet

Aug 14, 2026

Aug 13, 2026

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript - AOL.ca

Aug 13, 2026

Lineage Cell Therapeutics (LCTX) Falls 3.6% to $1.06 as Biotech Sentiment WeighsDealer Gamma - Vinanet

Aug 13, 2026

Aug 11, 2026

Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright - MarketBeat

Aug 11, 2026

Aug 10, 2026

Lineage Cell Therapeutics (LCTX) Climbs 3.18% to $1.14 as Buyers Defend Key SupportRisk Reward Setups - Vinanet

Aug 10, 2026

Aug 09, 2026

Lineage Cell Therapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 09, 2026

Aug 08, 2026

CCORF Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Aug 08, 2026